Shanghai Changzheng Hospital

🇨🇳China
Ownership
Private
Established
1955-01-01
Employees
-
Market Cap
-
Website
http://www.shczyy.com
Clinical Trials
Related News

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

First Posted Date
2024-12-05
Last Posted Date
2024-12-12
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
24
Registration Number
NCT06718270
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Carvedilol and Alverine in Portal Hypertension

Phase 2
Not yet recruiting
Conditions
Hypertension, Portal
Interventions
Drug: Carvedilol and alverine
First Posted Date
2024-11-20
Last Posted Date
2024-11-20
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
30
Registration Number
NCT06696248

Efficacy and Safety of LC-Z300-01 on Proteinuria in Diabetic Patients

Not Applicable
Not yet recruiting
Conditions
Diabetic Nephropathy
First Posted Date
2024-11-13
Last Posted Date
2024-11-13
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
60
Registration Number
NCT06686758
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC Patients

Early Phase 1
Not yet recruiting
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
Drug: HNF4α srRNA
First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
9
Registration Number
NCT06621173

Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
75
Registration Number
NCT06603376
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, China

The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis

First Posted Date
2024-09-19
Last Posted Date
2024-10-22
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
1000
Registration Number
NCT06589154
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

Early Phase 1
Recruiting
Conditions
Renal Cell Carcinoma
Interventions
Biological: anti-CD70-CAR-T cells
First Posted Date
2024-09-19
Last Posted Date
2024-10-22
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
9
Registration Number
NCT06586658
Locations
🇨🇳

Changzheng hospital, Shanghai, Shanghai, China

Endocrine and Exocrine Secretory Function Alterations After Moderately Severe and Severe Acute Pancreatitis

Not yet recruiting
Conditions
Acute Pancreatitis (AP)
Diabetes Mellitus
First Posted Date
2024-09-11
Last Posted Date
2024-09-19
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
120
Registration Number
NCT06590935

Hyperglycemia and Acute Pancreatitis

First Posted Date
2024-09-10
Last Posted Date
2024-09-19
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
4500
Registration Number
NCT06590233

Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy

Not yet recruiting
Conditions
Thyroid Associated Ophthalmopathy
First Posted Date
2024-09-10
Last Posted Date
2024-09-10
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
150
Registration Number
NCT06590220
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy